Subtype
Ocular Melanoma
CI-CAN-00001295Explore in graph →
62 active trials1 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001295Explore in graph →
Clinical trials
254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (36)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05607095 | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma | recruiting | Phase 1 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05903937 | Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases(HAITILS-PHP) | not yet recruiting | Phase 1 | 6 | Vastra Gotaland RegionOTHER_GOV | 0 |
| Sep 9, 2026 |
| clinicaltrials |
| NCT07183852 | Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma(GoTIL-01) | not yet recruiting | Phase 1 | 18 | Vastra Gotaland RegionOTHER_GOV | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07076550 | A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma | terminated | Phase 1 | 5 | Alpha-9 Oncology USA Inc.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT03025256 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | active not recruiting | Phase 1 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04855435 | Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | recruiting | Phase 1 | 106 | MonTa Biosciences ApSINDUSTRY | 2 | Aug 10, 2026 | clinicaltrials |
| NCT07747935 | Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma(Uveal Melanoma) | not yet recruiting | Phase 1 / Phase 2 | 30 | ReBio PharmaINDUSTRY | 0 | Aug 5, 2026 | clinicaltrials |
| NCT05415072 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | active not recruiting | Phase 1 / Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 7 | Jul 28, 2026 | clinicaltrials |
| NCT05098210 | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer | recruiting | Phase 1 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06626516 | Tebentafusp-tebn With LDT in Metastatic UM | recruiting | Phase 1 / Phase 2 | 109 | Thomas Jefferson UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04328844 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | active not recruiting | Phase 1 | 210 | iOncturaINDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT03635632 | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | active not recruiting | Phase 1 | 94 | Baylor College of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07501117 | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | recruiting | Phase 1 | 15 | Inge Marie SvaneOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06940739 | A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel | recruiting | Phase 1 / Phase 2 | 42 | Iovance Biotherapeutics, Inc.INDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT05075993 | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | active not recruiting | Phase 1 | 352 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | recruiting | Phase 1 / Phase 2 | 336 | IDEAYA BiosciencesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT07627698 | Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma(DUET-MEL) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05341349 | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | terminated | Phase 1 | 1 | Emory UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07203391 | Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis(TRIUMPH) | recruiting | Phase 1 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05496686 | Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma | active not recruiting | Phase 1 | 16 | Modulation Therapeutics, Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05628883 | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | completed | Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT02858869 | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | completed | Phase 1 | 25 | Emory UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03865212 | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma | terminated | Phase 1 | 12 | Mayo ClinicOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | terminated | Phase 1 | 78 | Fusion Pharmaceuticals Inc.INDUSTRY | 3 | Jan 7, 2026 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT04082962 | Dexamethasone Implant for Retinal Detachment in Uveal Melanoma | completed | Phase 1 | 10 | Ivana K. KimOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07136181 | Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma(NBM-BMX-UM) | recruiting | Phase 1 / Phase 2 | 36 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT06784648 | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 3 | Nov 19, 2025 | clinicaltrials |
| NCT04935229 | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma | terminated | Phase 1 | 67 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Oct 22, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT04812470 | Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases(HAITILS) | completed | Phase 1 | 8 | Vastra Gotaland RegionOTHER_GOV | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05893654 | Melphalan Chemoreduction for Ocular Melanoma(MELCOM) | enrolling by invitation | Phase 1 / Phase 2 | 10 | Hospital das Clínicas de Ribeirão PretoOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04283890 | PHP and Immunotherapy in Metastasized UM(CHOPIN) | active not recruiting | Phase 1 / Phase 2 | 83 | Leiden University Medical CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05004025 | Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma | completed | Phase 1 | 10 | HonorHealth Research InstituteOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 230 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT07063875 | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression(SILVER) | recruiting | Phase 1 / Phase 2 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT03922880 | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma | completed | Phase 1 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT04463368 | Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases(SCANDIUM II) | completed | Phase 1 | 18 | Vastra Gotaland RegionOTHER_GOV | 1 | Mar 28, 2025 | clinicaltrials |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | terminated | Phase 1 | 31 | Turnstone Biologics, Corp.INDUSTRY | 2 | Mar 10, 2025 | clinicaltrials |
| NCT05169957 | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) | completed | Phase 1 | 2 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04364230 | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)(Mel66) | completed | Phase 1 / Phase 2 | 22 | Craig L Slingluff, JrOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04879017 | FHD-286 in Subjects With Metastatic Uveal Melanoma | terminated | Phase 1 | 76 | Foghorn Therapeutics Inc.INDUSTRY | 3 | Apr 25, 2024 | clinicaltrials |
| NCT03052127 | Study in Subjects With Small Primary Choroidal Melanoma | completed | Phase 1 / Phase 2 | 57 | Aura BiosciencesINDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03068624 | Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | unknown | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT04729543 | MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer(MC2TCR) | recruiting | Phase 1 / Phase 2 | 20 | Erasmus Medical CenterOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04589832 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 6 | Arkadiusz Z. Dudek, MDOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04904120 | Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy(TIMAR1) | completed | Phase 1 | 7 | Perspective TherapeuticsINDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 4 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
Data updated 14 days agoSource updated Sep 15, 2026source: clinicaltrials